Identification And validation of transcription factor genes involved in prostate cancer metastasis

References

• Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, et al. 2014. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 25:638–651. doi:10.1016/j.ccr.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM. 2010. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 17:1511–1523. doi:10.1038/cdd.2010.20.
   PubMed Web of Science ®Google Scholar
• Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. 2007. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 7:64. doi:10.1186/1471-2407-7-64.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. doi:10.1016/j.neo.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. 2014. Cytohubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S11.
   PubMed Web of Science ®Google Scholar
• Clarke NW, Hart CA, Brown MD. 2009. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl. 11:57–67. doi:10.1038/aja.2008.29.
   Web of Science ®Google Scholar
• Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 2003. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4:P3.
   PubMed Web of Science ®Google Scholar
• Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. 2020. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 5:28. doi:10.1038/s41392-020-0134-x.
   PubMed Web of Science ®Google Scholar
• Guo L, Lin M, Cheng Z, Chen Y, Huang Y, Xu K. 2019. Identification of key genes and multiple molecular pathways of metastatic process in prostate cancer. PeerJ. 7:e7899. doi:10.7717/peerj.7899.
   Web of Science ®Google Scholar
• Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ. 2019. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 76:89–97. doi:10.1016/j.eururo.2018.11.045.
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Lyubimov A, Costa RH. 2006. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66:1712–1720. doi:10.1158/0008-5472.CAN-05-3138.
   PubMed Web of Science ®Google Scholar
• Labbe DP, Brown M. 2018. Transcriptional regulation in prostate cancer. Cold Spring Harb Perspect Med. 8. doi:10.1101/cshperspect.a030437.
   Web of Science ®Google Scholar
• Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, Weirauch MT. 2018. The Human Transcription factors. Cell. 175:598–599. doi:10.1016/j.cell.2018.09.045.
   PubMed Web of Science ®Google Scholar
• Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR. 2007. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 67:8504–8510. doi:10.1158/0008-5472.CAN-07-0673.
   PubMed Web of Science ®Google Scholar
• LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL. 2002. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62:4499–4506.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang X, Olumi AF. 2007. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 67:2247–2255. doi:10.1158/0008-5472.CAN-06-3793.
   PubMed Web of Science ®Google Scholar
• Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, Tsai SY, Tsai MJ. 2016. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 7:11418. doi:10.1038/ncomms11418.
   PubMed Web of Science ®Google Scholar
• Liu LY, Guo KM, Liang ZW, Li FB, Wang HL. 2018. Identification of candidate genes that may contribute to the metastasis of prostate cancer by bioinformatics analysis. Oncol Lett. 15:1220–1228. doi:10.3892/ol.2017.7404.
   PubMed Web of Science ®Google Scholar
• Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, et al. 2008. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68:2132–2144. doi:10.1158/0008-5472.CAN-07-6055.
   PubMed Web of Science ®Google Scholar
• Parrish RS, Spencer HJ. 2004. 3rd, Effect of normalization on significance testing for oligonucleotide microarrays. J Biopharm Stat. 14:575–589. doi:10.1081/BIP-200025650.
   PubMedGoogle Scholar
• Piechaczyk M, Blanchard JM. 1994. c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol. 17:93–131. doi:10.1016/1040-8428(94)90021-3.
   PubMedGoogle Scholar
• Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al. 2015. Integrative clinical genomics of advanced prostate cancer. Cell. 162:454. doi:10.1016/j.cell.2015.06.053.
   PubMed Web of Science ®Google Scholar
• Saha AK, Contreras-Galindo R, Niknafs YS, Iyer M, Qin T, Padmanabhan K, Siddiqui J, Palande M, Wang C, Qian B, et al. 2020. The role of the histone H3 variant CENPA in prostate cancer. J Biol Chem. 295:8537–8549. doi:10.1074/jbc.RA119.010080.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. doi:10.1101/gr.1239303.
   PubMed Web of Science ®Google Scholar
• Shrestha RL, Ahn GS, Staples MI, Sathyan KM, Karpova TS, Foltz DR, Basrai MA. 2017. Mislocalization of centromeric histone H3 variant CENP-A contributes to chromosomal instability (CIN) in human cells. Oncotarget. 8:46781–46800. doi:10.18632/oncotarget.18108.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A, Statistics C. 2021. CA Cancer J Clin. 71(2021):7–33. doi:10.3322/caac.21654.
   Google Scholar
• Siegel RL, Miller KD, Jemal A, Statistics C. 2017. CA Cancer J Clin. 67(2017):7–30. doi:10.3322/caac.21387.
   Google Scholar
• Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article3. doi:10.2202/1544-6115.1027.
   PubMedGoogle Scholar
• Sun X, Clermont PL, Jiao W, Helgason CD, Gout PW, Wang Y, Qu S. 2016. Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers. Int J Cancer. 139:899–907. doi:10.1002/ijc.30133.
   Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. doi:10.1093/nar/gkx247.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. doi:10.1016/j.ccr.2010.05.026.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. 2007. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 39:41–51. doi:10.1038/ng1935.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. 2015. Proteomics. Tissue-based map of the human proteome. Science. 347:1260419. doi:10.1126/science.1260419.
   PubMed Web of Science ®Google Scholar
• Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. 2005. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 8:393–406. doi:10.1016/j.ccr.2005.10.001.
   PubMed Web of Science ®Google Scholar
• Xu N, Chen SH, Lin TT, Cai H, Ke ZB, Dong RN, Huang P, Li XD, Chen YH, Zheng QS. 2020. Development and validation of hub genes for lymph node metastasis in patients with prostate cancer. J Cell Mol Med. 24:4402–4414. doi:10.1111/jcmm.15098.
   Web of Science ®Google Scholar
• Xu Y, Ma X-p, An J-n, Zhang Z-j, Ding J, Qu Y-k, Liu Z-l, Lin N. 2015. Short-time QiBaoMeiRan formula treatment exerts estrogenic activities without side effects on reproductive tissues in immature mice. Sci Rep. 5:17436. doi:10.1038/srep17436.
   PubMed Web of Science ®Google Scholar
• Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 22:2790–2799. doi:10.1200/JCO.2004.05.158.
   PubMed Web of Science ®Google Scholar
• Zhang XP, Zhang L, Yang HM, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. 2007. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 67:9425–9434. doi:10.1158/0008-5472.Can-07-1310.
   PubMed Web of Science ®Google Scholar